NCT00650156View on ClinicalTrials.gov

Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2007

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

adalimumab

40 mg single sc dose

BIOLOGICAL

adalimumab

80 mg single sc dose

Trial Locations (1)

200001

Site Reference ID/Investigator# 7181, Shanghai

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY